RxDoctor Payments Data

Shari Klein, DO

Internal Medicine · Las Vegas, NVNPI 1205854478

Payments from drug & device makers

$1,007in general payments, 2019–2025

Across 27 payments — averaging $37.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$215
  • Boehringer Ingelheim$208
  • AbbVie$166
  • Abbott$129
  • Amgen$86
  • Astellas Pharma US Inc$61
  • plus $142 from 8 others

What the payments were for

  • Food & beverage$94694%
  • Education$616%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,007 in reported general payments places this provider in the 70th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$49,465
Medicare patients
148
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$30,057
TrulicityDulaglutide22$26,089
JardianceEmpagliflozin33$25,867
OzempicSemaglutide26$25,034
SynthroidLevothyroxine Sodium69$7,514
SymbicortBudesonide/Formoterol Fumarate16$4,817
Methenamine Hippurate23$2,230
Levothyroxine Sodium135$2,032
Galantamine ErGalantamine Hbr13$1,697
Ipratropium Bromide49$1,478
Valsartan27$1,383
Celecoxib38$1,259
ValacyclovirValacyclovir Hcl17$1,255
Rosuvastatin Calcium111$1,009
Omeprazole82$898

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$30,05741 claims
Lilly USA, LLCTrulicity$215$26,08922 claims
Boehringer IngelheimJardiance$208$25,86733 claims
AbbVieSynthroid$166$7,51469 claims
AstraZenecaSymbicort$18$4,81716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →